Sorrento Therapeutics Inc

Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG™, COVIDROPS™, COVISHIELD™, FUJOVEE™ (Abivertinib) and OQORY™ (Covi-MSC), and diagnostic test solutions, including COVITRACK™ and COVIMARK™. The COVISTIX™ COVID-19 Virus Rapid Antigen Detection Test is approved under Emergency Use Authorization (EUA) in Mexico by COFEPRIS and in Brazil by ANVISA and cleared for commercialization.

Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia (PHN). RTX has cleared for Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients. SEMDEXA announced highly statistically significant positive top-line results from its Phase III Pivotal Trial C.L.E.A.R Program for its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica). ZTlido® was approved by the FDA on February 28, 2018.

The Sofusa® Lymphatic Delivery System (S-LDS) is a new method of treatment designed to deliver injectable medicines directly into lymphatic and systemic capillaries just beneath the epidermis via a proprietary microneedle and microfluidics system. Pre-Clinical models demonstrate potential benefits of lymphatic targeting with Sofusa proprietary nano-draped microneedles: >40-fold increase in drug concentration in lymph nodes vs subcutaneous injections (SC) or intravenous (IV) infusions; Improved tumor penetration with 1/10th dose; Improved anti-tumor efficacy and reduced metastases.